Lexaria Bioscience Corp. (NASDAQ: LEXX) Building A Global Presence With Superior Delivery Technology For Wide Range Of Drugs And Active Pharmaceutical Ingredients


(MENAFN- Investor Brand Network)

  • Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
  • Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
  • With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company's efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements...

Read More>>

NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at

About CBDWire

CBDWire
(“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text“CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
/Disclaimer

CBDWire
Denver, CO

303.498.7722 Office
...

CBDWire is powered by
IBN

MENAFN15032024000224011066ID1107981026


Investor Brand Network

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.